ChiCTR-TRC-13003417
暂停或中断
/
/
/
2013-08-06
/
/
卒中
機械手及經顱磁刺激聯合療法對中風病人手部運動功能康復的研究
機械手及經顱磁刺激聯合療法對中風病人手部運動功能康復的研究
機械手及經顱磁刺激聯合療法對中風病人手部運動功能康復的研究
随机平行对照
其它
randomly
/
NA
/
63
/
2013-07-01
1990-01-01
/
1) patients aged 18 or above; 2) first-ever ischemic subcortical stroke with onset time less than 21 days; 3) hand weakness as a result of stroke; 4) intracerebral hemorrhage excluded by brain computed tomography (CT) / magnetic resonance imaging (MRI); 5) the patient or his/her legally acceptable representative is willing to provide written informed consent.;
请登录查看1) personal history of epilepsy; 2) metallic implants in any part of body; 3) implanted cardiac pacemaker, defibrillator, medication pump or any other implanted electronics; 4) severe skull fracture, serious head injury, history of brain or spinal cord surgery; 5) brain tumour or other significant non-ischemic brain lesion on CT/MRI; 6) administration of drugs that potentially lower seizure threshold; 7) severe hand spasticity, open hand wound or hand deformity; 8) history of malignancy; 9) severe co-existing systemic diseases, severe dementia or psychosis; 10) inability to be followed up at regular interval; 11) pregnancy or breast-feeding.;
请登录查看Division of Neurology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong
/
Division of Neurology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong的其他临床试验
Division of Neurology, Dept of Medicine and Therapeutics, PWH的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

